Related Experiment Video

Updated: Jun 6, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
10:02

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Investigation of the Effects of Methylphenidate on Hemodynamic Parameters in Children With ADHD

Caglar Charles Daniel Jaicks1, Selman Vefa Yıldırım2

  • 1Department of Child and Adolescent Psychiatry, Istanbul Aydin University, Istanbul, Turkey.

Pharmacology Research & Perspectives
|June 5, 2026
PubMed

Insights

Methylphenidate (MPH) significantly increases blood pressure, heart rate, and prolongs cardiac intervals in children with Attention Deficit Hyperactivity Disorder (ADHD). Underweight children showed a higher prevalence of rhythm abnormalities after MPH administration.

Area of Science:

  • Pediatric Cardiology
  • Pharmacology
  • Neurodevelopmental Disorders

Background:

  • Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder in children.
  • Methylphenidate (MPH) is a widely prescribed stimulant medication for ADHD.
  • Understanding the acute cardiovascular effects of MPH in pediatric populations is crucial for safe treatment initiation.

Purpose of the Study:

  • To investigate the acute hemodynamic and electrocardiographic effects of a single 10 mg dose of methylphenidate (MPH) in children newly diagnosed with ADHD.
  • To assess changes in blood pressure, heart rate, and cardiac intervals (QTc, PR, QRS) post-MPH administration.
  • To evaluate the prevalence of ECG rhythm abnormalities and their association with BMI percentile.

Main Methods:

  • Prospective observational study involving 60 children (6-16 years) with newly diagnosed ADHD.
  • Administration of a single 10 mg dose of short-acting MPH.
  • Measurement of hemodynamic (blood pressure, heart rate) and electrocardiographic parameters (QTc, PR, QRS intervals, rhythm) before and 30-45 minutes after MPH intake.
  • Interpretation of all measurements by a pediatric cardiologist.

Main Results:

  • Significant increases in systolic blood pressure (p<0.001), diastolic blood pressure (p<0.001), and heart rate (p<0.001) were observed post-MPH.
  • Significant prolongation of QTc (p<0.001), PR (p<0.001), and QRS durations (p<0.001) occurred.
  • ECG rhythm abnormalities were noted in 15.0% of participants (p=0.002), with a markedly higher prevalence (75.0%) in children below the 5th BMI percentile (p<0.001).

Conclusions:

  • A single 10 mg dose of MPH induces acute, measurable cardiovascular changes in children with ADHD.
  • Underweight children (below 5th BMI percentile) exhibit a significantly higher risk of developing MPH-induced cardiac rhythm disturbances.
  • Close monitoring of blood pressure and ECG is recommended during the initiation of MPH treatment in pediatric ADHD patients, especially those who are underweight.

Keywords:
ADHDelectrocardiographyhemodynamicsmethylphenidate

More Related Videos

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol13:09

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol

Published on: April 1, 2018

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...